Vantage Reports

Drawing on Evaluate data, Vantage reports provide an in-depth view on trends in the biotech, pharma and medtech sectors. Our special reports also provide a detailed look at some of the industry's hottest topics.

H1 Round Up: The haves and the have-nots

Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…

H1 Round Up: The haves and the have-nots

Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…

ADA/EASL eBook

June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…

ADA/EASL eBook

June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…

ASCO 2023 Round Up

The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…

ASCO 2023 Round Up

The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…